Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

09 mai 2019 16h10 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review

CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
01 mai 2019 08h00 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
08 avr. 2019 08h30 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases

CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
29 mars 2019 08h00 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis

CAMBRIDGE, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
19 mars 2019 08h00 HE | Source: Spero Therapeutics, Inc.

Spero Announces Appointment of Cynthia Smith to its Board of Directors

CAMBRIDGE, Mass., March 19, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
01 mars 2019 08h30 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics to Present at March Investor Conferences

CAMBRIDGE, Mass., March 01, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
26 févr. 2019 08h00 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720

CAMBRIDGE, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
04 févr. 2019 07h00 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994

CAMBRIDGE, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
29 janv. 2019 08h00 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Initiation of SPR720 Phase 1 Clinical Trial

CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
07 janv. 2019 16h01 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial

CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...

Page suivante